Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Rhea-AI Summary

Cytokinetics (Nasdaq: CYTK) announced inducement equity awards made on December 15, 2025 to 10 employees who began work in November–December 2025. The company granted 21,399 stock options and 14,422 restricted stock units (RSUs) to be settled in common stock.

The RSUs vest over 3 years (40%/40%/20% annual schedule). Options vest over 4 years (25% at one year, then monthly over 36 months), have a $62.16 exercise price (closing price on Dec 15, 2025) and a 10-year term. Awards follow Nasdaq Listing Rule 5635(c)(4).

News Market Reaction – CYTK

-3.55%

-3.55% Session close to close

In the Dec 17 session, CYTK declined 3.55%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details standard inducement equity awards—21,399 stock options and 14,422 RSUs—to ...

Analysis

This announcement details standard inducement equity awards—21,399 stock options and 14,422 RSUs—to 10 recent hires, with options priced at $62.16, matching the grant-date close. The vesting schedules span 3–4 years, linking compensation to ongoing service. In context, Cytokinetics recently reported substantial cash reserves, continuing clinical progress for aficamten, and a positive European regulatory opinion. Investors tracking dilution and incentive structures may monitor future equity grants alongside upcoming regulatory decisions and financial updates.

Key Figures

Stock options granted: 21,399 shares RSUs granted: 14,422 RSUs Employees receiving awards: 10 employees +5 more

8 metrics

Stock options granted 21,399 shares Inducement grants to new employees on Dec 15, 2025

RSUs granted 14,422 RSUs Inducement grants to new employees on Dec 15, 2025

Employees receiving awards 10 employees New hires starting in November and December 2025

Option exercise price $62.16 per share Equal to CYTK closing price on Dec 15, 2025

RSU vesting period 3 years 40%/40%/20% vesting schedule on grant anniversaries

Option vesting period 4 years 1/4 after one year, then monthly vesting over 36 months

Option term 10 years Expiration duration for granted stock options

RSU vesting split 40% / 40% / 20% First, second, and third anniversaries of grant date

Historical Context

5 past events · Latest: Dec 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 12	Regulatory opinion	Positive	+4.3%	Positive CHMP opinion recommending EU approval for MYQORZO in obstructive HCM.
Nov 18	Inducement grants	Neutral	-1.2%	Equity inducement awards for new hires under Nasdaq Rule 5635(c)(4).
Nov 17	Strategic initiative	Positive	+0.8%	Support for AHA initiative to improve hypertrophic cardiomyopathy care.
Nov 10	Clinical data	Positive	+3.4%	MAPLE-HCM data showing aficamten superiority over metoprolol on key measures.
Nov 05	Earnings update	Neutral	+1.9%	Q3 2025 financials with large cash balance and ongoing late-stage programs.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent value-driving catalysts have been regulatory and clinical updates, which usually saw positive price reactions, while routine inducement grants drew a mild negative response.

Recent Company History

Over the last six weeks, Cytokinetics reported Q3 2025 financials, additional positive MAPLE-HCM data, a supportive American Heart Association initiative, an earlier round of inducement grants, and, most recently, a positive CHMP opinion for MYQORZO (aficamten) with an expected EU decision in Q1 2026. Clinical and regulatory milestones generally coincided with share gains, while the prior inducement grant on Nov 15, 2025 was followed by a modest decline.

Key Terms

restricted stock units, RSUs, Nasdaq Listing Rule 5635(c)(4), exercise price, +2 more

6 terms

restricted stock units financial

"and 14,422 restricted stock units (RSUs) that will be settled in shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"14,422 restricted stock units (RSUs) that will be settled in shares"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

Nasdaq Listing Rule 5635(c)(4) regulatory

"material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"The stock options that were granted are subject to an exercise price of $62.16"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

equity incentive plan financial

"subject to the terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

vesting financial

"RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 15, 2025 it granted stock options to purchase an aggregate of 21,399 shares of common stock and 14,422 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 10 employees, whose employment commenced in November and December 2025 as a material inducement to their employment.

The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant date, in each case, subject to each respective employee’s continued service with the Company. The stock options that were granted are subject to an exercise price of $62.16 per share, which is equal to the closing price of the Company’s common stock on December 15, 2025 and will vest over 4 years, with 1/4^th of the shares underlying the employee’s option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting in monthly installments at a rate of 1/48^th of the shares underlying such stock options over the subsequent 36 months, subject to each respective employee’s continued service with the Company. The stock options have a 10-year term. These awards are subject to the terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan and the applicable award agreements pursuant to which the awards were granted.

The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. In addition, Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), ulacamten, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Disclaimer

Aficamten, omecamtiv mecarbil, ulacamten and CK-089 are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission particularly under the caption “Risk Factors” in Cytokinetics’ latest Annual Report on Form 10-K. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

FAQ

What equity awards did Cytokinetics (CYTK) grant on December 15, 2025?

Cytokinetics granted 21,399 stock options and 14,422 RSUs to 10 new employees on December 15, 2025.

How do the RSUs issued by CYTK vest and when do they pay out?

The RSUs vest over 3 years: 40% at year 1, 40% at year 2, and 20% at year 3, subject to continued service.

What are the terms and exercise price of the CYTK stock options granted?

Options vest over 4 years (25% at one year then monthly), carry a 10-year term and an exercise price of $62.16 per share.

Why did Cytokinetics issue these option and RSU grants under Nasdaq Rule 5635(c)(4)?

The awards were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

How many employees received inducement grants from CYTK in December 2025?

A total of 10 employees who commenced employment in November and December 2025 received the inducement grants.

Will the CYTK awards be settled in shares and what plan governs them?

The RSUs will be settled in common stock upon vesting, and all awards are subject to the company's Amended and Restated 2004 Equity Incentive Plan and applicable award agreements.